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a  b  s  t  r  a  c  t
End-of-life  (EoL)  care1 is  increasingly  used  as a generic  term  in  preference  to palliative  care  or  terminal
care,  particularly  with  reference  to individuals  with  chronic  disease,  who  are  resident  in  community
and  long-term  care  (LTC)  settings.  This  review  evaluates  studies  based  on  patient  reported  outcome
measures  (PROMS)  of  quality  of  EoL  care  across  all health-care  settings.  From  1041  citations,  12 studies
were  extracted  by searches  conducted  in  EBSCO,  Scopus,  Web  of  Science,  PubMed,  Cochrane,  Open  Grey
and  Google  Scholar  databases.
At  present,  the  evidence  base  for  EoL  care  is  founded  on  cancer  care.  This review  highlights  the paucity
of  studies  that  evaluate  quality  of EoL  care  for patients  with  chronic  disease  outside  the established
cancer-acute  care  paradigm,  particularly  in LTC.  This  review  highlights  the  absence  of  any  PROMs  for
the  estimated  60%  of  patients  in  LTC  with  cognitive  impairment.  Patient-reported  outcomes  (PROs)  are
critical  to understanding  how  EoL  care  services  and  practices  affect  patients’  health  and  EoL experience.
PROMs  describe  the  quality  of  care  from  the  patient’s  perspective  and  add  balance  to  existing  clinical  or
proxy-derived  knowledge  on  the  quality  of care  and  services  provided.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1 The term EoL care has evolved as an umbrella term that encompasses all aspects of care related to death and dying provided towards the end of life [2]. There is no
consensus in the literature regarding the time-frame it is applied to; deﬁnitions range from care in the last year of life, to care from time of terminal diagnosis until death.
However, it is generally accepted as representing a broad continuum of care for people who  are living with, or dying from terminal illness [1]. This wide focus lends itself to
the  description of care for patients with non-malignant chronic diseases where disease trajectories are more protracted, and prognostication less certain than for patients
with  cancer.
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1. Introduction
1.1. Rationale
By 2050, there will be 392 million people worldwide aged 80
years and over; more than three times the current number [3]. In
developed countries, this demographic transition is underpinned
by an epidemiological transition from high infant and maternal
mortality, and high infectious disease rates, to low premature mor-
tality and a predominance of chronic, non-communicable disease
[4]. In congruence with population ageing, societies are ageing,
and social environments are changing. Traditional, family-based
options for EoL care are becoming less common [5]. Family size is
decreasing and perspectives on intergenerational care of older peo-
ple are shifting [6]. People are dying later in life, increasingly from
chronic disease, and more frequently in LTC than at home [7].
Chronic diseases include cardiovascular disease, hypertension,
stroke, cancer, diabetes, arthritis, chronic obstructive pulmonary
disease (COPD), dementia, and depression. Cardiovascular diseases
account for the majority (46%) of chronic disease deaths globally,
followed by cancers (22%), respiratory diseases (10.5%) and dia-
betes (4%) [8].The prevalence of these diseases typically increases
with age, and multi-morbidity is a common feature. Approximately
80% of older adults have at least one chronic disease, and 68% have
at least two [9]. Chronic diseases are the leading cause of mortality
worldwide, representing 60% of all deaths globally [10].
The proportion of U.S. deaths in LTC was 23% in 2008, this ﬁgure
is projected to rise to 40% by 2040 [11]. This trend is mirrored else-
where, in New Zealand [12], Australia [13], Canada [14], Ireland
[7], and the U.K. [6]. A study of prevalence of chronic medical
conditions in older residents in LTC in the U.S. found that the lead-
ing three chronic diseases were; hypertension (men 53%, women
56%), dementia (men 45%, women 52%), and depression (men 31%,
women 37%) [15]. A study of patterns of chronic co-morbid med-
ical conditions in older residents in LTC in the U.S. found that the
most frequent two co-morbid disease combination in both men  and
women was hypertension and dementia [16]. It is estimated that
as many as 60% of patients in LTC have cognitive impairment or
dementia, many of whom do not have a formal diagnosis [17–20].
Evaluating EoL care for patients with cancer presents fewer
methodological challenges than for other chronic disease popula-
tions. In comparison to other leading chronic diseases, cancer has
a more predictable trajectory towards death, and more certainty in
prognostication [21–23]. Consequently, much of the research to-
date in evaluating EoL care has focused on patients with cancer in
its associated care settings. Originally, PROMs of EoL care focused
on the evaluation of physical symptoms, recently, their scope has
broadened to include psycho-social factors, well-being, spiritual-
ity, mental health, communication and quality of life [24]. There
are several condition-speciﬁc PROMs for patients with different
types of cancer; typically these measures focus on symptoms such
as pain, dyspnea, and nausea, in addition to subjective aspects of
the patients’ experience of EoL care.
While many of the physical symptoms experienced by cancer
patients are common to other chronic disease populations, the
patient experience at EoL is often different. Patients with non-
malignant disease experience more burdensome symptoms in the
last year of life than those suffering from cancer, not only because
of the greater number of symptoms, but also because of the more
protracted trajectory of decline in chronic conditions [25,26]. A
gradual deterioration in functioning, punctuated by intermittent
acute episodes is typical in conditions such as COPD and heart
failure. Frail elderly patients and those with dementia typically
experience a prolonged and progressive functional decline from
an already low baseline of physical and cognitive function [27]. As
a result, many of these patients use multiple healthcare settings for
EoL care.
1.2. Objectives
Currently, the evidence base for EoL care is founded on the
cancer-acute care paradigm [28]. Development of the evidence base
necessitates measurement of the patient experience beyond these
conﬁnes. The objectives of this review were to identify, describe
and critically evaluate existing PROMs of quality of EoL care, for
patients with chronic disease, in various healthcare settings.
2. Methods
2.1. Eligibility criteria
Papers were identiﬁed based on the following inclusion criteria:
1. Primary research studies based wholly or partially on PROs of
EoL care, or that validate PROMs of EoL care
2. Sample of adults (18 years of age and over) with any chronic
disease or condition
3. Conducted in any type of health-care setting
4. Using assessment measure(s) with described psychometric
properties
5. Reported in English and published between January 2006 and
July 2016 (inclusive)
The following exclusion criteria were used:
1. Studies based on samples where cancer is the sole diagnosis
2. Clinical trials and studies addressing technical interventions,
physiological, laboratory-based, or radiological outcomes
3. Descriptive, non-clinical articles (e.g., reviews, discussion pieces,
reports, expert statements)
2.2. Information sources and searches
A systematic review of the literature was conducted during
July 2016. Searches were conducted in Academic Search Com-
plete, CINAHL Plus with full text, PsycINFO, Scopus, Web  of Science,
PubMed, and Cochrane databases. The Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines
were used in this systematic review [29]. The search strategy
included a combination of free text and controlled vocabulary
(MeSH) terms. The search strategy used three groups of terms com-
bined with AND: “end of life care”, “patient reported outcomes”,
and “scale”. Details of the electronic search strategy, including
search terms used are shown in Table 1. The grey literature was
searched using Open Grey and Google Scholar databases.
Studies were examined for inclusion in a two-step process, with
an initial screening of titles and abstracts, followed by screening of
full-text articles against the inclusion criteria to identify relevant
studies.
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Table 1
Electronic search strategy and search terms used.
Search # Academic search
completea
CINAHL plus with
full texta
PsycINFOa PubMedb Scopusc Web  of
scienced
Cochrane
databasese
#1 “end of life care” 10,000 5530 3819 7147 8548 20,812 40
#2  “end of life care” ** 5602 91 788 1970 6343 12,032 39
#3  “end of life care” OR “terminal care” OR
“hospice care” OR “palliative care” OR “end
stage care” **
19,394 711 2734 13,423 35,388 12,354 61
#4  “patient reported outcome” OR “patient
reported outcome measure” OR “patient self
report” OR “patient outcome assessment” OR
“patient outcome measure” **
77,094 24 205 2931 10,270 2837 537
#5  scale OR measure OR instrument OR survey
OR questionnaire **
1,409,119 17,217 65,517 504,296 3,128,448 2,698,016 7819
#6  (#3 AND #4 AND #5) ** 721 0 11 47 122 34 38
** Limiters applied.
a EBSCO (Academic Search Complete, CINAHL Plus, PsycINFO) Limiters: Publication date 2006–2016; English language.
b PubMed Limiters: Publication date 2006–2016; English language and Humans.
c Scopus Limiters: Publication date 2006–2016; English language.
d Web  of Science Limiters: Publication date 2006–2016, English language.
e Cochrane Limiters: Publication date 2006–2016.
Searches in EBSCO and PubMed were saved and updated with
weekly alerts and RSS feeds from July to September 2016 to ensure
that any eligible studies published subsequent to the ﬁnal search
date were not missed. No further studies were identiﬁed for inclu-
sion via alerts or feeds. Data was extracted from the identiﬁed
articles and tabulated according to author and date, characteristics
of the studies and key features of the measures used.
The measures used in the identiﬁed studies were reviewed and
psychometrically evaluated according to quality criteria adapted
from Terwee et al., [30] and Selman et al., [31]. Speciﬁc adaptations
made were as follows: due to the lack of an agreed ‘gold standard’
for PROs of quality of care, criterion validity was not assessed; as
the instruments reviewed were patient-reported, inter-rater agree-
ment was deemed not to be relevant and test-retest reliability was
used as a more appropriate test of reliability; as no scoring system
was used, the quality criterion for ‘no information found’ was given
a not reported (NR) rating instead of 0; the term ‘doubtful’ in the
criteria for indeterminate rating was changed to ‘inadequate’; due
to the complexity of deﬁning minimally important change (MIC)
for quality of care, the requirement that the MIC  be deﬁned to sat-
isfy the interpretability criterion was omitted. The adapted criteria
used are shown in Table 2.
3. Results
3.1. Study selection
The database searches yielded 966 articles, searches of the grey
literature, journals, reviews, and the Internet resulted in an addi-
tional 75 articles, yielding a total of 1041 articles. Eliminating
duplicates gave a total of 940 articles for screening. The total num-
ber of articles retained post-screening was 24, the full text of these
articles was retrieved and reviewed for ﬁnal eligibility. Twelve arti-
cles were excluded for the following reasons: not based on PROs
(n = 1), not EOL care (n = 3), based exclusively on sample of patients
with cancer (n = 4), did not report or describe psychometric proper-
ties of assessment used (n = 3), was a descriptive/non clinical article
(n = 1). A total of 12 studies were included in the ﬁnal review.
A ﬂowchart of the stages of the review process according to the
PRISMA guidelines is shown in Fig. 1.
3.2. Study characteristics
Of the 12 studies included in the review, six were primary
research studies and six were validation studies. The studies were
based in a range of settings, three in hospitals; three in commu-
nity settings; four in multiple settings; and two in hospice settings.
The patients sampled had a variety of diagnoses, two  studies were
based on patients with Multiple Sclerosis (MS); two on patients
with HIV/AIDS; three on patients with unspeciﬁed chronic dis-
ease; and ﬁve on palliative care patients, predominantly, but not
exclusively with a cancer diagnosis.
A total of 15 PROMs of quality of EoL care in patients with chronic
disease were identiﬁed across the 12 studies included. Study char-
acteristics, PROMs used, and their key features are shown in
Tables 3 and 4. The majority of measures used ﬁve or eleven–point
Likert rating scales and reported administration times of 10 min
or less. The exception was the MCOHPQ, with a reported admin-
istration time of 25–30 min. Administration time for the Quality
Measure for Palliative Nursing was not reported.
3.3. Synthesis of results
The psychometric properties of the included measures, eval-
uated according to criteria adapted from Terwee et al. [30] and
Selman et al. [31] are presented in Table 5. Of the 15 measures eval-
uated, ten demonstrated adequate content validity. No information
on target population involvement was found for the MCOHPQ, and
the remaining four measures had an indeterminate rating as they
lacked a clear description of the development process.
Six measures demonstrated adequate internal consistency.
Three of the measures, the PHQ-9, the SKIPP and the MVQOLI, had
an indeterminate rating for internal consistency, predominantly
due to a lack of factor analysis. Five measures showed poor internal
consistency: the MCOHPQ, the QOC, the SEC-P and the African POS.
No information on internal consistency was  found for the Quality
Measure for Palliative Nursing.
Nine of the measures demonstrated adequate construct valid-
ity. Testing of three measures used an inadequate design or method.
The SEC-P demonstrated poor construct validity, and no informa-
tion on construct validity was found for the MCOHPQ and the
Quality Measure for Palliative Nursing.
Seven measures, the POS, the MSIS, the SAS, the PHQ, the HADS-
D, the BHI, and the African POS, demonstrated adequate test-retest
reliability. Test-retest reliability was  indeterminate for the SKIPP
due to doubtful design in testing. No information on test-retest reli-
ability was found for the remaining seven of the ﬁfteen measures.
No information on responsiveness was available for eight
measures. The PHQ and the HADS-D both demonstrated ade-
quate responsiveness. Of the remaining ﬁve measures four had
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Table  2
Quality criteria for psychometric evaluation of measures.
Property Deﬁnition Quality criteria a, b
1. Content validity The extent to which the domain of interest is
comprehensively sampled by the items in the
questionnaire
+  A clear description is provided of the measurement aim, the target population, the
concepts that are being measured, and the item selection AND target population and
(investigators OR experts) were involved in item selection;
?  A clear description of above-mentioned aspects is lacking OR only target population
involved OR inadequate design or method;
−  No target population involvement;
NR No information found on target population involvement.
2.  Internal consistency The extent to which items in a (sub)scale are
intercorrelated, thus measuring the same
construct
+ Factor analyses performed on adequate sample size (7 * # items and ≥100) AND
Cronbach’s alpha(s) calculated per dimension AND Cronbach’s alpha(s) between 0.70
and  0.95;
? No factor analysis OR inadequate design or method;
− Cronbach’s alpha(s)  ˛ < 0.70 or  ˛ > 0.95, despite adequate design and method;
NR No information found on internal consistency.
3.  Construct validity The extent to which scores on a particular
questionnaire relate to other measures in a
manner that is consistent with theoretically
derived hypotheses concerning the concepts
that are being measured
+ Speciﬁc hypotheses were formulated AND at least 75% of the results are in
accordance with these hypotheses;
? Inadequate design or method (e.g., no hypotheses);
− Less than 75% of hypotheses were conﬁrmed, despite adequate design and methods;
NR No information found on construct validity.
4.  Reliability The extent to which patients can be
distinguished from each other, despite
measurement errors (relative measurement
error)
+ ICC or weighted Kappa ≥0.70;
? Inadequate design or method (e.g., time interval not mentioned);
−  ICC or weighted Kappa <0.70, despite adequate design and method;
NR No information found on reliability.
5.  Responsiveness The ability of a questionnaire to detect
clinically important changes over time
+ SDC or SDC<MIC OR MIC outside the LOA OR RR >1.96 OR AUC≥0.70;
? Inadequate design or method;
− SDC or SDC≥MIC  OR MIC equals or inside LOA OR RR≤1.96 OR AUC<0.70, despite
adequate design and methods;
NR No information found on responsiveness.
6.  Floor and ceiling effects The number of respondents who achieved the
lowest or highest possible score
+ ≤15% of the respondents achieved the highest or lowest possible scores;
?  Inadequate design or method;
− >15% of the respondents achieved the highest or lowest possible scores, despite
adequate design and methods;
NR No information found on interpretation.
7.  Interpretability The degree to which one can assign qualitative
meaning to quantitative scores
+ Mean and SD scores presented of at least four relevant subgroups of patients
?  Inadequate design or method OR less than four subgroups;
NR No information found on interpretation.
Table adapted from Terwee et al. [30].
MIC  = minimal important change; SDC = smallest detectable change; LOA = limits of agreement; ICC = Intraclass correlation; SD, standard deviation.
a + = positive rating; ? = indeterminate rating; − = negative rating; NR = not reported.
b Inadequate design or method = lacking of a clear description of the design or methods of the study, sample size smaller than 50 subjects (should be at least 50 in every
(subgroup) analysis), or any important methodological weakness in the design or execution of the study.
an indeterminate rating and one, the SEC-P, demonstrated poor
responsiveness.
No information on ﬂoor and ceiling effects was found for eight of
the measures reviewed. Five measures demonstrated ﬂoor/ceiling
effects despite adequate design and methods. Two measures, the
POS-MSS and the MVQoLI demonstrated low ﬂoor/ceiling effects.
One measure, the SAS demonstrated adequate interpretability.
No information on interpretability was found for eleven of the mea-
sures and three had an indeterminate rating.
4. Discussion
The aim of this review was to identify, describe and critically
evaluate existing PROMs of quality of EoL care for patients with
chronic disease, in various healthcare settings. A total of 15 PROMs
of quality of EoL care in patients with chronic disease were identi-
ﬁed across 12 studies.
4.1. Summary of evidence
The measures identiﬁed were heterogeneous in terms of their
constituent domains. Physical symptoms and perceptions of qual-
ity of care or experiences of care were the most frequently
occurring domains, with both occurring in nine of the 15 mea-
sures identiﬁed. Quality of life (QoL) or well-being featured as a
domain in ﬁve measures, emotional/psychosocial symptoms fea-
tured in ﬁve measures, spiritual status featured in three measures,
anxiety/depression featured in three measures and healthcare pro-
fessionals’ communication skills featured in three measures. These
ﬁndings highlight that there is broad agreement across the PROMs
identiﬁed, in that the evaluation of quality of EoL care requires mul-
tidimensional PROMs, encompassing both subjective and objective
indicators. However, these ﬁndings also demonstrate the absence
of consensus on what the essential, core domains for measurement
should be.
The majority of studies were conducted in a single setting, with
mixed, cancer–predominant populations. None of the studies iden-
tiﬁed were based in LTC settings. However, a small number (n = 3) of
the patients sampled in Higginson’s study [38] were nursing home
residents.
None of the measures identiﬁed included patients with cogni-
tive impairment in their validation study samples. The BHI, POS,
SEC-P, QEOLC and QOC, all specify exclusion of patients with cog-
nitive impairment in their validation study samples. Cognitive
impairment was not speciﬁed as an exclusion criterion for the
remaining measures; however various inclusion criteria used, such
as the ability to remember and report [35], and to be mentally well-
enough [42] act as de facto barriers to participation from patients
with cognitive impairment. No cognitive impairment/dementia-
speciﬁc PROMs were identiﬁed, and no adaptations of the PROMs
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Table 3
Study characteristics and measures used.
1st author &Year Instrument Country Sample Setting Constructs
measured
Domains No. of items Scoring Admin. time Period of
reference
Study type
Addington-Hall
2014 [32]
St. Christopher’s
Index of Patient
Priorities
(SKIPP)
U.K. n = 35
Palliative care
patients,
predominantly
with a cancer
diagnosis (71%)
Hospice service
with inpatient
unit (60%), and
day care
services (40%)
Patients’ perceptions
of  the impact of the
service on their
well-being while
providing a broad
indication of
patients’ own
perceived quality of
life  (QoL)
QoL, Concerns,
change in
concerns,
impact of
service on
concerns
8 7 point
numerical scale
for QoL items, 2
open questions
for  concerns, 5
point rating
scales for
changes and
impacts items
7 min Current
perception and
‘before starting
hospice care’
Validation
study
Cameron  2015
[33]
Quality Measure
for Palliative
Nursing
U.K.  n = 11
Palliative care
patients,
diagnosis not
reported
Community
palliative care
service
Quality of care
provided by
palliative care
specialist nurses
from the patients’
perspective
Personal
characteristics,
communication
skills,
knowledge,
relationship
with patient and
providing
comfort
15 Not reported Not reported Not reported Validation
study
Currow  2015
[34]
Symptom
Assessment
Scale (SAS)
Australia n = 19, 747
Palliative care
patients (85%
cancer)
Hospital and
community
Symptom distress:
pain, insomnia,
nausea, bowel
problems, appetite
problems, breathing
problems, and
fatigue
Insomnia,
appetite,
nausea, bowels,
breathing,
fatigue and pain
7 11 point
Likert-type
verbal  rating
scale
<10 min In  the last 24 h Primary
research
study
Curtis  2013 [35] Quality of
Communication
(QOC)*;
Quality of End of
Life Care
(QEOLC)**;
Patient Health
Questionnaire
(PHQ-8)***
U.S. n = 1717
Patients with
chronic disease
and palliative
needs, cancer,
COPD,  heart
failure  &liver
disease
Hospital *Overall quality of
communication and
speciﬁc aspects of
communication
**Patient-reported
quality of EoL care
***Depressive
Symptoms
*General
communication
skills,
communication
about EoL care
**Patient-
centred systems,
communication
skills,  symptom
skills, affective
skills,
patient-centred
values
***Threshold
disorders,
subthreshold
disorders
*18
**26
***8
*11 point Likert
scale
**11 point Likert
scale
***Score 0–24
*Not reported
**Described as
’short’ but time
not speciﬁed
***<3 min
*In the last 6
months, and if
patient
remembered the
encounter with
the clinician
**In the last  2
weeks
***In the last 2
weeks
Primary
research
study
Gade  2008 [36] Modiﬁed City of
Hope Patient
Questionnaire
(MCOHPQ)
U.S.  n = 517
Hospitalized
patients with
life limiting
illness,
predominantly
cancer, COPD
&organ failure
Hospital Physical symptoms,
psychosocial,
emotional, and
spiritual status and
health care
experiences
Physical area,
emo-
tional/relationship
area, spiritual
area, place of
care/environment,
care providers
communication
95 11 point Likert
scales
25–30 min Current
perception
Primary
research
study
Harding  2012
[37]
African
Palliative
Outcome Scale
(African POS)
Southern
&Eastern
Africa
n  = 1337
Patients with
HIV
Public Health
Clinics, Hospice,
and palliative
care  services
(home-based
and in-patient
units)
Respondent’s
perceptions
regarding a different
dimension of care or
need  in a palliative
care setting
Physical
&psychological
well-being,
inter-personal
well-being,
existential
well-being
7 (+3 family
oriented
items)
Items scored
from  0–5
10 min In  the last 3  days Validation
study
T.
 K
earns
 et
 al.
 /
 M
aturitas
 96
 (2017)
 16–25
 
21
Table 4
Study characteristics and measures used (cont.).
1st author
&year
Instrument Country Sample Setting Constructs
measured
Domains No. of items Scoring Admin. time Period of
reference
Study type
Higginson 2008
[38]
Palliative Care
Outcome Scale
(POS) *,
Palliative Care
Outcome
Scale-MS
symptoms
(POS-MSS)**
&MS Impact
Scale (MSIS)***
U.K. n = 52
Patients with
advanced MS with
palliative care
needs
Various – home
87%, nursing
home 6%, 2%
each in
hospital, rehab
unit, day care
and residential
home
Patient
outcomes
following
introduction of
a  new palliative
care service
*Anxiety,
patient &carer
concerns, and
practical needs
**MS
symptoms
***QoL and
impact of MS
*8
**18
***29
*5 point Likert
scale
** 5 point
Likert scale
*** rated 1–5
*10 min
**10 min
***5–8 min
*  In the last 3
days
**In the last 3
days
*** In the last 2
weeks
Primary
research study
Krevers  2014
[39]
Sense of
Security in Care
– Patients’
Evaluation
(SEC-P)
Sweden n = 161
Patients in
palliative stage of
incurable disease,
cancer or other
non-malignant
severe or lethal
disease
Palliative
home-care
units
Patients’ sense
of security in
palliatve care
Care
Interaction,
identity and
mastery
15 6 point Likert
scale
10 min Current
perception
Validation
study
Krug  2010 [40] Palliative Care
Outcome Scale
(POS)
U.S. n = 67
Patients with
advanced HIV/AIDS
attending
outpatient clinic at
a teaching hospital
Hospital
Outpatient
Clinic
Respondent’s
perceptions
regarding a
different
dimension of
care or need in
a palliative care
setting
Physical,
psychological,
and spiritual
10 5 point Likert
scale (8 items)
3 point Likert
scale (2 items)
10 min In the last 3
days
Primary
research study
Mayahara 2015
[41]
*Hospital
Anxiety and
Depression
Scale (HADS-D)
**Brief Hospice
Inventory (BHI)
U.S. n = 46
Hospice program
patients (60%
cancer)
Hospice * Depression
**QoL
* Symptoms of
anxiety and
depression
** Physical
&psychological
symptoms,
patients’
perceptions of
hospice care,
and patients’
ratings of QoL
*7 (Depression
subscale)
**9 (QoL
subscale)
* Items scored
on a scale of
0–3
**11 point
Likert scale
*2–6 min
**<10 min
* In the last
week
**In the last
few days
Primary
research study
Selman  2011
[42]
Missoula Vitas
Quality of Life
Index
(MVQOLI)
South
Africa and
Uganda
n = 285
Palliative care
patients with HIV
(81%), cancer (18%)
and MND
Hospices, home
care, day care,
outpatient and
inpatient
clinics
QOL in the
context of
advanced,
progressive,
incurable
illness
Symptoms,
function,
interpersonal,
well-being,
transcendent
26 5 point scale 10–15 min Current
perception
Validation
study
Sleeman  2013
[43]
*Palliative Care
Outcome Scale
(POS)
**POS-MS-
Symptoms
(POS-MSS)
U.K. n = 46
Patients with MS
with palliative care
needs
Setting not
reported,
interviews
were mainly
conducted in
patients’
homes
Psychological
well-being and
perceived
quality of care
*Patient and
family anxiety,
patient and
carer concerns
and practical
problems
**Items
speciﬁcally
relating to MS
symptoms
*8
**18
*5 point Likert
scale
**5 point Likert
scale
* <10 min
** 10 min
In the last 3
days
Validation
study
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Table 5
Psychometric evaluation of identiﬁed measures.
Instrument Content
validity
Internal
consistency
Construct
validity
Test – retest reliability Responsiveness Floor/ceiling effects Interpretability Validation population
BHI [41,44] ? + ? + ? NR NR U.S., Hospice patients,
patients with dementia were
excluded, n = 145
HADS-D  [41,45,46] ? − + + + NR NR U.K., Patients in a general
medical hospital outpatient
clinic, n ≥ 250
MCOHPQ [36,47] NR − NR NR NR NR NR U.S., Sample size not reported
MSIS  [38,48–50] + + + + ? − NR U.K., MS  patients, n ≥ 1000
MVQOLI  [51,42] + ? ? NR NR + ? U.S., Hospice patients, n = 257
PHQ  [35,52–54] + ? + + + NR NR U.S., Primary care patients,
n  = 357
POS  [38,55,40,43] + + + + − − ? U.K., Palliative care patients
without ‘impaired mental
status’, n = 148
POS  African version [56,37,57] + − + + ? NR NR Africa, HIV/cancer patients,
n = 80
POS-MSS  [38,43,58,59] + + + NR NR + NR U.K., MS  patients, n = 50
QEOLC  [35,60] + + + NR NR − ? U.S., Patients with
life-limiting diseases (cancer,
COPD, HF) without dementia
or  delirium, n = 801
QOC  [61,62] ? − + NR NR − NR U.S., Patients with AIDS,
n  = 104, without cognitive
impairment or dementia
Qual  measure for palliative nursing [33] + NR NR NR NR NR NR U.K., Palliative care patients,
n = 11
SAS  [63,34] ? + + + ? NR + Australia, Cancer &MI, n = 572
SEC-P  [39] + − − NR NR − NR Sweden, Palliative care
patients, n = 161, ‘cognitive
failure/confusion’ used as an
exclusion criterion
SKIPP  [32,64] + ? ? ? NR NR NR U.K., Palliative care patients,
n = 35
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Fig. 1. PRISMA ﬂowchart of stages of the review process.
identiﬁed for use with patients with cognitive impairment were
reported.
The POS, a generic mutidimensional PROM was found to be one
of the more robust measures identiﬁed, with good content validity,
internal consistency, construct validity and test-retest reliability.
The POS was the only measure reviewed that was used in a research
study that included patients with cognitive impairment in the study
sample, although the number of such participants was not reported
[38]. The POS-MS, a version of the POS adapted for use with patients
with MS,  demonstrates good psychometric properties for validity
criteria and ﬂoor and ceiling effects, however, the small sample
size and lack of data for reliability and responsiveness indicate that
further testing and validation is required.
Based on a large validation sample of over 1000 patients with
Multiple Sclerosis (MS), the MSIS shows a strong psychometric
proﬁle with respect to validity and reliability. However, the mea-
sure’s condition speciﬁcity may  limit its adaptation and use in other
chronic disease populations. The QEOLC also shows good psycho-
metric properties for content and construct validity and internal
consistency. However, further testing of its test-retest reliability
and responsiveness are required.
The majority of the validation study samples of the included
measures are small, with samples of less than 250 subjects [65]. The
measures with the smallest validation study sample sizes, the SKIPP
(n = 35), and the Quality Measure for Palliative Nursing (n = 11),
both score poorly on the quality criteria used. This inevitably raises
questions regarding design adequacy and methodological strength.
However, as both measures are relatively new, further testing of
validity and reliability is required.
Responsiveness is an important property in PROMs for eval-
uating quality of EoL care, yet only two measures, the PHQ and
the HADS, demonstrated adequate responsiveness. Both are unidi-
mensional measures of anxiety and depression symptoms, where
signiﬁcant change may  be more easily quantiﬁed (using SDC, MIC,
or GRR) than for multidimensional measures.
Overall, the measures evaluated were found to lack psycho-
metric quality and methodological rigor. However, a number of
considerations need to be made when evaluating PROMs of EoL
care. The difﬁculty in deﬁning what is minimal important change
(MIC) for this population, impacts on the application of the respon-
siveness and interpretability criteria. Floor and ceiling effects
are relevant only where the measure under consideration has
a total score or subscale scores. Additionally, the methodolog-
ical challenges inherent in carrying out research with patients
at EoL with chronic disease, frequently preclude the recruitment
and retention of the large study samples required for factor
analyses.
Another consideration is the difference in the constructs mea-
sured across the various measures identiﬁed. The POS, African POS,
MCOHPQ, QEOLC, BHI, MVQOLI and the SKIPP are generic, mul-
tidimensional PROMS that measure quality of care in relation to
general health or well-being; the POS-MS and MSIS are condition-
speciﬁc PROMS that measure quality of care in relation to MS
symptoms; the SAS, PHQ-8 and HADS are symptom-speciﬁc, uni-
dimensional measures; and the QOC, SEC and Quality Measure for
Palliative Nursing measure communication, patients’ sense of secu-
rity and nursing skills, respectively. The time-frame across which
quality of care was measured also varied, ranging from ‘current per-
ception’ to ‘in the last 6 months’. These disparities pose a challenge
in drawing clear comparisons among the measures included in this
review, and as such they were evaluated individually with respect
to their psychometric properties.
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A signiﬁcant limitation of this review is that only articles written
in English were included, and important studies in other languages
may  have been omitted as a result. Additionally, the limit on pub-
lication dates from 2006 to 2016 may  have excluded additional
relevant studies. Finally, a review of the qualitative literature would
have enhanced the clarity of the theoretical bases for the concept of
quality of care and its related constructs, but was beyond the scope
of this review.
The ﬁndings of this review underline the lack of PROMS of
EoL care for patients with chronic disease outside the cancer care
model, and the absence of any PROMs of EoL care developed or
validated for use with patients with cognitive impairment. Further
research is required to develop of a core set of PROs for use with
patients with non-malignant chronic disease, across multiple EoL
care settings and disease trajectories.
5. Conclusion
Extension of the current evidence base requires further research
to develop and adapt PROMs for the growing population of patients
with chronic disease who reside in non-acute care settings, partic-
ularly in LTC.
The inherent methodological challenges in evaluating EoL care
in this population necessitate the development of alternative meth-
ods of assessment and appraisal. Given the proportion of patients
in LTC with cognitive impairment, the development of appropri-
ate PROMs for this population will require the inclusion of these
patients in study samples and the adaptation of measures to suit
participants with varying levels of cognition.
This review highlights the need for a high quality PROM of
quality of EoL care for patients with chronic disease beyond the
established acute care-cancer paradigm, to include patients with
varying levels of cognition. The development of a wider selection
of context sensitive, methodologically sound and psychometrically
robust PROMs is an essential step towards improving the quality of
EoL care for our ageing populations and chronically ill.
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